Understanding this will be important if we are to use Topo VI as an antibiotic target in those bacteria that have the enzyme.

The resultant product contains the gene of interest flanked on each end by a conserved, five-nucleotide topoisomerase-binding/cleavage site [(C/T)CCTT]. The six additional bases establish ...

Like quinolone-based antibiotics that have been in use since the 1960s, gepotidacin acts on bacterial type IIA topoisomerases, DNA-unwinding enzymes. It originates however from a structurally ...

The FDA has approved Blujepa (gepotidacin) for the treatment of female patients 12 years of age and older weighing at least 40kg with uncomplicated UTI.

The drug functions by inhibiting bacterial DNA replication through ... pathogens while ensuring balanced inhibition of Type II topoisomerase enzymes. In January 2025, GSK secured breakthrough ...